194 related articles for article (PubMed ID: 14597742)
1. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia.
Rudin CM; Cohen EE; Papadimitrakopoulou VA; Silverman S; Recant W; El-Naggar AK; Stenson K; Lippman SM; Hong WK; Vokes EE
J Clin Oncol; 2003 Dec; 21(24):4546-52. PubMed ID: 14597742
[TBL] [Abstract][Full Text] [Related]
2. Topical ONYX-015 in the treatment of premalignant oral dysplasia: another role for the cold virus?
Ganly I; Singh B
J Clin Oncol; 2003 Dec; 21(24):4476-8. PubMed ID: 14597746
[No Abstract] [Full Text] [Related]
3. Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies.
Makower D; Rozenblit A; Kaufman H; Edelman M; Lane ME; Zwiebel J; Haynes H; Wadler S
Clin Cancer Res; 2003 Feb; 9(2):693-702. PubMed ID: 12576437
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.
Ganly I; Kirn D; Eckhardt G; Rodriguez GI; Soutar DS; Otto R; Robertson AG; Park O; Gulley ML; Heise C; Von Hoff DD; Kaye SB
Clin Cancer Res; 2000 Mar; 6(3):798-806. PubMed ID: 10741699
[TBL] [Abstract][Full Text] [Related]
5. Image analysis of p53 and cyclin D1 expression in premalignant lesions of the oral mucosa.
Liu SC; Hu Y; Sauter ER; Clapper ML; Chen SY; Lanfranchi HE; Engstrom PF; Klein-Szanto AJ
Anal Quant Cytol Histol; 1999 Apr; 21(2):166-73. PubMed ID: 10560487
[TBL] [Abstract][Full Text] [Related]
6. Expression of p53, cyclin D1 and Ki-67 in pre-malignant and malignant oral lesions: association with clinicopathological parameters.
Raju B; Mehrotra R; Oijordsbakken G; Al-Sharabi AK; Vasstrand EN; Ibrahim SO
Anticancer Res; 2005; 25(6C):4699-706. PubMed ID: 16334163
[TBL] [Abstract][Full Text] [Related]
7. Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas.
Galanis E; Okuno SH; Nascimento AG; Lewis BD; Lee RA; Oliveira AM; Sloan JA; Atherton P; Edmonson JH; Erlichman C; Randlev B; Wang Q; Freeman S; Rubin J
Gene Ther; 2005 Mar; 12(5):437-45. PubMed ID: 15647767
[TBL] [Abstract][Full Text] [Related]
8. Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients.
Nemunaitis J; Cunningham C; Tong A; Post L; Netto G; Paulson AS; Rich D; Blackburn A; Sands B; Gibson B; Randlev B; Freeman S
Cancer Gene Ther; 2003 May; 10(5):341-52. PubMed ID: 12719704
[TBL] [Abstract][Full Text] [Related]
9. p53 expression above the basal cell layer in oral mucosa is an early event of malignant transformation and has predictive value for developing oral squamous cell carcinoma.
Cruz IB; Snijders PJ; Meijer CJ; Braakhuis BJ; Snow GB; Walboomers JM; van der Waal I
J Pathol; 1998 Apr; 184(4):360-8. PubMed ID: 9664901
[TBL] [Abstract][Full Text] [Related]
10. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions.
Tsao AS; Liu D; Martin J; Tang XM; Lee JJ; El-Naggar AK; Wistuba I; Culotta KS; Mao L; Gillenwater A; Sagesaka YM; Hong WK; Papadimitrakopoulou V
Cancer Prev Res (Phila); 2009 Nov; 2(11):931-41. PubMed ID: 19892663
[TBL] [Abstract][Full Text] [Related]
11. Alterations of rb pathway components are frequent events in patients with oral epithelial dysplasia and predict clinical outcome in patients with squamous cell carcinoma.
Soni S; Kaur J; Kumar A; Chakravarti N; Mathur M; Bahadur S; Shukla NK; Deo SV; Ralhan R
Oncology; 2005; 68(4-6):314-25. PubMed ID: 16020958
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical study of syndecan-1 down-regulation and the expression of p53 protein or Ki-67 antigen in oral leukoplakia with or without epithelial dysplasia.
Kurokawa H; Matsumoto S; Murata T; Yamashita Y; Tomoyose T; Zhang M; Fukuyama H; Takahashi T
J Oral Pathol Med; 2003 Oct; 32(9):513-21. PubMed ID: 12969225
[TBL] [Abstract][Full Text] [Related]
13. Markers for dysplasia of the upper aerodigestive tract. Suprabasal expression of PCNA, p53, and CK19 in alcohol-fixed, embedded tissue.
Coltrera MD; Zarbo RJ; Sakr WA; Gown AM
Am J Pathol; 1992 Oct; 141(4):817-25. PubMed ID: 1384338
[TBL] [Abstract][Full Text] [Related]
14. Expression of p53 protein in oral submucous fibrosis, oral epithelial hyperkeratosis, and oral epithelial dysplasia.
Chiang CP; Lang MJ; Liu BY; Wang JT; Leu JS; Hahn LJ; Kuo MY
J Formos Med Assoc; 2000 Mar; 99(3):229-34. PubMed ID: 10820956
[TBL] [Abstract][Full Text] [Related]
15. Differential expressions of cyclin-dependent kinase inhibitors (p27 and p21) and their relation to p53 and Ki-67 in oral squamous tumorigenesis.
Choi HR; Tucker SA; Huang Z; Gillenwater AM; Luna MA; Batsakis JG; El-Naggar AK
Int J Oncol; 2003 Feb; 22(2):409-14. PubMed ID: 12527941
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of repeated intraepithelial delivery of adenoviral p53 in patients with dysplastic oral leukoplakia.
Zhang S; Li Y; Li L; Zhang Y; Gao N; Zhang Z; Zhao H
J Oral Maxillofac Surg; 2009 May; 67(5):1074-82. PubMed ID: 19375021
[TBL] [Abstract][Full Text] [Related]
17. Cell cycle proteins and the development of oral squamous cell carcinoma.
Schoelch ML; Regezi JA; Dekker NP; Ng IO; McMillan A; Ziober BL; Le QT; Silverman S; Fu KK
Oral Oncol; 1999 May; 35(3):333-42. PubMed ID: 10621856
[TBL] [Abstract][Full Text] [Related]
18. Assessment of laminin-5 in oral dysplasia and squamous cell carcinoma.
Rani V; McCullough M; Chandu A
J Oral Maxillofac Surg; 2013 Nov; 71(11):1873-9. PubMed ID: 23891017
[TBL] [Abstract][Full Text] [Related]
19. Topical bleomycin for the treatment of dysplastic oral leukoplakia.
Epstein JB; Gorsky M; Wong FL; Millner A
Cancer; 1998 Aug; 83(4):629-34. PubMed ID: 9708924
[TBL] [Abstract][Full Text] [Related]
20. P53 and cyclin D1 staining patterns of malignant and premalignant oral lesions in age-dependent populations.
Castle JT; Cardinali M; Kratochvil FJ; Abbondanzo SL; Kessler HP; Auclair PL; Yeudall WA
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 1999 Sep; 88(3):326-32. PubMed ID: 10503863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
